3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
14
Injections
13
Pemetrexed
9
Specimen Handling
8
Carboplatin
8
tislelizumab
7
Interviews as Topic
7
Cisplatin
7
fludarabine
5
atezolizumab
5
Educational Status
5
Cyclophosphamide
5
Standard of Care
4
Practice Guidelines as Topic
4
Methods
4
Fluorouracil
4
Early Intervention, Educational
4
Capecitabine
4
Biopsy
4
Bevacizumab
4
Trastuzumab
3
Platinum
3
Paclitaxel
3
Oxaliplatin
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Docetaxel
3
Cetuximab
3
1,2-diaminocyclohexaneplatinum II citrate
3
toripalimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Blood Component Removal
×
Other solid neoplasm
×
30 days
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled